{
    "clinical_study": {
        "@rank": "166615", 
        "arm_group": [
            {
                "arm_group_label": "XS003 Dose-level 1", 
                "arm_group_type": "Experimental", 
                "description": "Capsule formulation"
            }, 
            {
                "arm_group_label": "XS003 Dose-level 2", 
                "arm_group_type": "Experimental", 
                "description": "Capsule formulation"
            }, 
            {
                "arm_group_label": "XS003 Dose-level 3", 
                "arm_group_type": "Experimental", 
                "description": "Capsule formulation"
            }, 
            {
                "arm_group_label": "Tasigna", 
                "arm_group_type": "Experimental", 
                "description": "Marketed capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will assess bioavailability of XS003 given as a single oral dose compared to\n      Tasigna\u00ae given as a single oral dose in healthy male subjects."
        }, 
        "brief_title": "Pharmacokinetic Comparison of XS003 and Tasigna", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The study consists of two parts, the first part is composed as a pilot part and compares the\n      bioavailability of single oral doses of XS003 compared to Tasigna\u00ae given as single oral dose\n      in healthy male subjects. The second part is a food-effect part which assesses the food\n      effect of a single oral dose of XS003 in healthy male subjects either fed or fasted. The\n      study will also evaluate safety and tolerability of XS003 as secondary objectives."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males\n\n          -  Age 18 to 55 years of age\n\n          -  Body mass index (BMI) of 18.0 to 29.0 kg/m2\n\n          -  Laboratory parameters in normal range\n\n        Exclusion Criteria:\n\n          -  Females\n\n          -  Current smokers and those who have smoked within the last 12 months. A breath \u2028carbon\n             monoxide reading of greater than 10 ppm at screening.\n\n          -  Serious adverse reaction or serious hypersensitivity to any drug or the\n             formulation\u2028excipients.\n\n          -  History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal\n             disease as judged by the investigator.\n\n          -  Subject has a QTcF>450 ms based on ECG at screening or a history of additional \u2028risk\n             factors for Torsades de Pointe (e.g. hypokalaemia, hypomagnesemia, a family \u2028history\n             of long QT syndrome)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068898", 
            "org_study_id": "XS003_CT001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "XS003 Dose-level 1", 
                    "XS003 Dose-level 2", 
                    "XS003 Dose-level 3"
                ], 
                "intervention_name": "XS003", 
                "intervention_type": "Drug", 
                "other_name": "RightSize Nilotinib"
            }, 
            {
                "arm_group_label": "Tasigna", 
                "intervention_name": "Tasigna", 
                "intervention_type": "Drug", 
                "other_name": "Nilotinib"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Quotient Clinical"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of \"XS003\" and Originator in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "XSpray Microparticles", 
            "last_name": "XSpray Microparticles", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetics measured by Area Under the Curve (AUC)", 
            "measure": "Bioavailability of Nilotinib", 
            "safety_issue": "No", 
            "time_frame": "3 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068898"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "XSpray Microparticles", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "XSpray Microparticles", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}